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Background: Complete pathological response occurs in 10–20% of patients with rectal cancer who are treated
with neoadjuvant chemoradiation therapy prior to pelvic surgery. The possibility that complete pathological
response of rectal cancer can also occur with neoadjuvant chemotherapy alone (without radiation) is an intriguing
hypothesis.
Case presentation: A 66-year old man presented an adenocarcinoma of the rectum with nine liver metastases
(T3N1M1). He was included in a reverse treatment, aiming at first downsizing the liver metastases by chemotherapy,
and subsequently performing the liver surgery prior to the rectum resection. The neoadjuvant chemotherapy
consisted in a combination of oxaliplatin, 5-FU, irinotecan, leucovorin and bevacizumab (OCFL-B). After a right portal
embolization, an extended right liver lobectomy was performed. On the final histopathological analysis, all lesions
were fibrotic, devoid of any viable cancer cells. One month after liver surgery, the rectoscopic examination showed
a near-total response of the primary rectal adenocarcinoma, which convinced the colorectal surgeon to perform
the low anterior resection without preoperative radiation therapy. Macroscopically, a fibrous scar was observed at
the level of the previously documented tumour, and the histological examination of the surgical specimen did not
reveal any malignant cells in the rectal wall as well as in the mesorectum. All 15 resected lymph nodes were free of
tumour, and the final tumour stage was ypT0N0M0. Clinical outcome was excellent, and the patient is currently alive
5 years after the first surgery without evidence of recurrence.
Conclusion: The presented patient with stage IV rectal cancer and liver metastases was in a unique situation linked
to its inclusion in a reversed treatment and the use of neoadjuvant chemotherapy alone. The observed
achievement of a complete pathological response after chemotherapy should promote the design of prospective
randomized studies to evaluate the benefits of chemotherapy alone in patients with stages II-III rectal adenocarcinoma
(without metastasis).
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Colorectal cancer (CRC) is a major public health problem
[1,2]. Over the last two decades, its management has im-
proved significantly, in parallel to the implementation of
dedicated multidisciplinary oncological rounds [3,4]. Rou-
tine staging is now in place in almost all centers with the
use of MRI and/or endo-rectal ultrasonography. Surgery
has been standardized thanks to the popularization of the
total mesorectal excision technique. In addition, neoad-
juvant treatment has been refined with the use of chemo-
radiotherapy (CRT) in selected patients with locally
advanced cancer. More recently, the survival of patients
with metastatic rectal cancer has also improved thanks to
the availability of new potent drug combinations.
To illustrate these improvements in the (neo-) adjuvant
treatments, up to 10% of patients with stage IV CRC do
not have detectable liver metastasis anymore on pathology
following chemotherapy [5,6]. Pathologic complete re-
sponse (pCR) also occurs in 10-20% of patients with rectal
cancer who are treated with neoadjuvant chemo radio-
therapy prior to pelvic surgery [7]. The current standard
management of patients with rectal cancer reaching the
peri-rectal fat (cT3-T4N0) and/or with a clinical evidence
of lymphnode invasion (cTxN1) includes a neoadjuvant
chemoradiotherapy [8]. At our institution, for patients
with advanced synchronous colorectal liver metastasis
(CRLM) and a non- obstructive primary tumor, a reversed
protocol [9,10] is recommended. They include patients
with multiple, often large metastases not accessible for
minor (up to two segments) up-front liver resection [10].Figure 1 Radiological findings of the primary tumour. CT scan and PetThis strategy controls the CRLM and the primary tumour,
hence increasing the curative liver metastatic resection. In
our initial study [11], patients with advanced liver metas-
tases (clinical risk score [CRS] of 3–5), were treated with
highly effective chemotherapy, proving respectability and
survival rate were better than expected. Neoadjuvant
chemotherapy has helped achieving control of the CRLM
in more than 80% of cases, and of the primary tumour (as
well as of invaded lymph-nodes) in more than 60% of
cases [12]. A total of 92 patients have been now managed
by a reversed treatment, and seven patients demonstrated
complete histological responses of all metastases after
chemotherapy.
The possibility that pCR of rectal cancer may occur
without neoadjuvant radiation therapy is an intriguing
hypothesis, which could promote the use of neoadjuvant
chemotherapy alone also for non-metastatic colorectal
cancer. The described patient with rectal cancer and liver
metastasis was included in a “reversed” management pro-
tocol, aiming at treating the disease by chemotherapy first,
and further resecting the liver metastases and the primary
rectal cancer sequentially [9-11]. This unique type of man-
agement allowed for the assessment of the pathological
response to chemotherapy alone.
Case presentation
A 66-year old man presented with an adenocarcinoma
of the rectum located 10 cm from the anal verge (uT3N1)
(Figure 1). Thoraco-abdominal PET/CT scan revealed
nine liver metastases (Figure 2). There were two lesions in-scan of the rectal tumour prior to chemotherapy.
Figure 2 Computed tomography scan of liver metastases prior and after surgery: axial view A– H). Liver metastases in all liver segments
except segment 1. I) CT scan after surgery. extended right hepatectomy showing no recurrence.
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ment V and VII, and three in segment VI. The carcinoem-
bryonic antigen (CEA) was 8.3 μG/L. The clinical risk
score was of two according to Fong’s classification (posi-
tive lymph node status, and multiple synchronous liver
metastases).
Neoadjuvant chemotherapy consisted in a combination
of oxaliplatin, 5-fluorouracil, irinotecan, leucovorin and
bevacizumab (OCFL-B). Our strategy aimed at control-
ling the metastatic disease and performing liver surgery
prior to rectal surgery, according to a “reversed” proto-
col previously described [9,11]. After three cycles, the
patient did not report rectal bleeding anymore, and a
major response of the liver metastases was documented
on magnetic resonance imaging (MRI); all nine second-
ary tumours had decreased in size. After a right portal
vein embolization, an extended right liver lobectomy
with the local resection of two lesions in segment III
was performed. On the final histopathological analysis,all lesions were fibrotic nodules, devoid of any viable
cancer cells and compatible with previous metastases.
One month after liver surgery, a rectoscopic examin-
ation showed a near-total response of the primary rectal
adenocarcinoma, which convinced the colorectal sur-
geon to proceed with pelvic surgery without preopera-
tive radiation therapy. A low anterior resection of the
rectum was carried out. Macroscopically, a fibrous scar
was observed at the level of the previously documented
tumour, and the histological examination of the surgical
specimen did not reveal any malignant cells in the rectal
wall as well as in the mesorectum. All 15 removed lymph
nodes were free of tumour, and the final tumour stage was
therefore ypT0N0M0 (Figure 3).
This response was associated to an excellent clinical out-
come: although the patient initially presented with bilobar
liver metastases, he is currently alive without signs of
recurrence five years after surgery. This confirms the
advantages of preoperative chemotherapy and resection
Figure 3 Radiological appearance, operative specimen and histological profile of the primary tumour. A. Pre-treatment PET scan showing
hypermetabolic lesion of the mid rectum. B. Operative specimen of low anterior resection showing a fibrous scar in the mid rectum.
C. Histological analysis of the operative specimen, showing the absence of tumour cells and the presence of fibrous tissue within the partially
reepithelialised rectal wall.
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sponse and hence predicts the survival rates [13].Conclusion
The current standard of care of patients with locally ad-
vanced rectal cancer includes the use of neoadjuvant
chemoradiotherapy. Overall, 10–20% of patients achieve
a complete rectal pathological response after chemoradia-
tion. Some investigators have even demonstrated a sus-
tained clinical response in the absence of rectal resection,
with a low recurrence rate of 4.6%, and five-year overall
and disease-free survival rates of 96 and 72% [14,15].
Despite these benefits, pelvic radiotherapy is linked to
a number of limitations. It induces a peri-rectal inflam-
mation, and the use of chemotherapy-only could make
surgery easier, with higher chances of achieving a resec-
tion with appropriate margins by a minimally invasive
approach. The use of radiotherapy in the management
of rectal cancer is making another curative pelvic radi-
ation impossible for potential prostatic, gynecological,bladder or anal cancer. In addition, it has long-term impact
on anorectal, urinary and sexual function [16,17]. Finally,
the recent improvements in the management of rectal
cancer, including chemoradiotherapy and total mesorectal
excision, have no impact on known or microscopic distant
metastases.
The present patient with pCR received a chemotherapy
combining oxaliplatin, 5-fluorouracil, irinotecan, leucovorin
and bevacizumab. Oxaliplatin-based neoadjuvant chemo-
therapy, currently mainly used in stage IV patients, may
represent an attractive alternative to the neoadjuvant ra-
diation therapy for rectal cancer. Induction chemother-
apy has the added advantage of earlier administration of
systemic therapy and may improve the control or the
prevention of distant metastasis.
Prospective randomized studies should be carried
out to demonstrate effectiveness of systemic therapy
into combined-modality programs and to evaluate the
benefit of chemotherapy alone in selected patients with
stages II-III rectal adenocarcinoma with or without dis-
tant metastasis.
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